Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Head and Neck Neoplasms 121 Lung Neoplasms 119 Glioblastoma 118 Carcinoma, Non-Small-Cell Lung 118 Breast Neoplasms 105 Lymphoma 102 Squamous Cell Carcinoma of Head and Neck 90 Central Nervous System Neoplasms 83 Prostatic Neoplasms 80 Leukemia 77 Pancreatic Neoplasms 67 Gliosarcoma 66 Rectal Neoplasms 63 Precursor Cell Lymphoblastic Leukemia-Lymphoma 63 Esophageal Neoplasms 63 Brain Neoplasms 59 Lymphoma, Large B-Cell, Diffuse 56 Lymphoma, Follicular 55 Lymphoma, Non-Hodgkin 49 Hodgkin Disease 48 Burkitt Lymphoma 46 Sarcoma 43 Lymphoma, Large-Cell, Immunoblastic 42 Leukemia, Lymphocytic, Chronic, B-Cell 42 Myelodysplastic Syndromes 37 Lymphoma, Mantle-Cell 36 Glioma 36 Neoplasms 34 Astrocytoma 34 Lymphoma, B-Cell, Marginal Zone 33

Interventions

tremelimumab 1 durvalumab 1 Sodium Chloride 1 Radiotherapy 1 Lidocaine 1 Hyperthermic Intraperitoneal Chemotherapy 1 Cystectomy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Invasive Bladder Cancer × Radiotherapy × Clear all

NCT03702179 2024-12-05

IMMUNOPRESERVE

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

32 enrolled 19 charts

Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡